688176.SH上海证券交易所 · 科创板 STAR
Jiangsu Yahong Meditech 亚虹医药
Chemical Pharmaceuticals 化学制药
¥14.73+¥0.04 · +0.27%
Open 开盘
¥14.58
High 最高
¥15.07
Low 最低
¥14.47
Prev Close 昨收
¥14.69
Volume 成交量
2,035.8万股
Turnover 成交额
¥3.00亿
Mkt Cap 总市值
¥84亿
P/E 市盈率
−17.1×
Recent Activity 近期动态All Filings 全部公告 →
6 significant filings since 30 May 2026: 2 on litigation, 2 on new listing and 2 on equity incentive. The latest, on 6 Aug 2026: 江苏亚虹医药科技股份有限公司关于仲裁进展暨提起仲裁反请求的公告.
自 30 May 2026 起有 6 份重大公告：litigation 2 份、new listing 2 份、equity incentive 2 份。最新一份（6 Aug 2026）：江苏亚虹医药科技股份有限公司关于仲裁进展暨提起仲裁反请求的公告。
5.007.5010.0012.5015.0017.50
Volume 成交量
6,107.8万
20222023202420252026
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥84亿 | ¥63亿 | 61st highest of 158 · 158 家中第 61 高 | |
| Trailing P/E 市盈率 | — | 38.6x | No value 无数据 | |
| P/B 市净率 | 6.2x | 2.5x | 27th highest of 157 · 157 家中第 27 高 | |
| Revenue Growth 营收增速 | 19.3% | 1.6% | 34th highest of 156 · 156 家中第 34 高 | |
| Profit Growth 净利增速 | -47.1% | 1.9% | 25th lowest of 158 · 158 家中第 25 低 | |
| Gross Margin 毛利率 | 74.2% | 50.2% | 30th highest of 155 · 155 家中第 30 高 | |
| Net Margin 净利率 | -157.7% | 9.8% | 4th lowest of 157 · 157 家中第 4 低 | |
| Return on Equity 净资产收益率 | -16.3% | 3.1% | 6th lowest of 157 · 157 家中第 6 低 | |
| Debt to Assets 资产负债率 | 27.8% | 28.0% | 78th lowest of 158 · 158 家中第 78 低 | |
| Grade Score 评级得分 | 34 | 51 | 30th lowest of 157 · 157 家中第 30 低 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
| Jiangsu Yahong Meditech 亚虹医药 | ¥84亿 | — | 6.2x | 19.3% | -157.7% | -16.3% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。